IGF-1 LR3

IGF Binding Proteins and the Free Fraction

UKPWritten and published by UK Peptides2 min readUpdated 3 cited sources

The short answer

IGF binding proteins sequester the overwhelming majority of circulating IGF-1, largely in a ternary complex with IGFBP-3 and the acid-labile subunit. Bound IGF-1 cannot engage its receptor, so this system controls how much is actually available.

Key facts

Binding protein family
Six IGFBPs
Dominant carrier
IGFBP-3
Third component
Acid-labile subunit (ALS)
Complex
Ternary: IGF-1 + IGFBP-3 + ALS
Effect
Extends half-life, restricts availability
Key review
Baxter, Horm Res 1994 (PMID 7532612)

What the system does

Six IGF binding proteins bind IGF-1 with high affinity. The dominant one in circulation is IGFBP-3, which forms a ternary complex with IGF-1 and the acid-labile subunit. That assembly is too large to leave the vascular compartment easily, which both prolongs IGF-1's presence and restricts where it can act.

Why sequestration is not simply a limitation

IGF-1 is a growth factor with receptors on nearly every tissue and structural similarity to insulin. Uncontrolled availability would be a problem, not a benefit. The binding protein system functions as a reservoir and a brake at once, holding a large circulating pool while keeping the free, active fraction small and regulated.

Research material referenced

IGF-1 LR3 1mg, third-party HPLC tested

Buy IGF-1 LR3 · £49.99

What the acid-labile subunit contributes

ALS is what makes the complex large enough to be retained in circulation. Its importance is demonstrated by what happens when it is missing: Domené and colleagues described acid-labile subunit deficiency in the Journal of Endocrinological Investigation in 2005, a condition in which the ternary complex cannot form and IGF-1 handling is substantially altered.

How LR3 evades it

Two modifications, both aimed at the same target. Arginine at position 3 replaces a glutamate whose negative charge contributes to binding protein interaction. The 13-residue N-terminal extension adds further interference. Together they substantially reduce IGFBP affinity, which raises the free fraction at a given total concentration.

What that means and does not mean

A larger free fraction means more is available to engage receptors at any moment. It does not mean more total activity in any simple sense, because the binding protein system also protects IGF-1 from clearance. Removing the reservoir function while removing the brake changes the whole profile, not just one part of it.

Why this matters for cell culture

Cultured cells secrete their own IGF binding proteins into the medium, which sequester added IGF-1 unpredictably. An analogue that resists them delivers more consistent availability from experiment to experiment. That is the practical reason LR3 exists as a laboratory reagent.

Frequently asked questions

How much circulating IGF-1 is free?

Only a small fraction. The overwhelming majority is bound, largely in the ternary complex with IGFBP-3 and the acid-labile subunit.

Why does the body sequester IGF-1?

It is a growth factor with receptors on nearly every tissue. The binding system acts as both a reservoir and a brake.

How does LR3 escape it?

Arginine at position 3 removes a charge contributing to binding, and a 13-residue N-terminal extension adds further interference.

Continue researching

Related guides and reference material.

Primary sources & clinical trials

Published papers, trial registrations, regulator pages and company announcements. Links open the original.

UKP

Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).

Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.

Corrections log

More IGF-1 LR3 articles

Research use only. The information above is provided for scientific and educational reference. Compounds referenced are not approved for human use and are supplied for in vitro research or reference-material purposes only. No efficacy, safety, or therapeutic claims are made.